Ultrasensitive HBsAg testing predicts HBsAg seroreversion outcomes: Considerations for new and existing therapies

J Hepatol. 2023 Nov 28:S0168-8278(23)05294-7. doi: 10.1016/j.jhep.2023.11.018. Online ahead of print.

Authors

Mark Anderson¹, Vera Holzmayer¹, Michael Stec¹, Gavin Cloherty¹, Seng Gee Lim²

Affiliations

¹ Abbott Laboratories, Abbott Diagnostics Division, Abbott Park, IL, USA.
² Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore; Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdclimsg@nus.edu.sg.

PMID: 38036010
DOI: 10.1016/j.jhep.2023.11.018

No abstract available

Publication types

Letter